Concord Biotech IPO GMP Today: ₹240
The GMP has been falling steadily since yesterday, but it is still significantly higher than the issue price. This suggests that there is still strong demand for the IPO, and that investors are expecting the shares to list at a premium.
The Concord Biotech IPO is a book-building issue, which means that the final issue price will be determined based on the demand for the shares. If the demand is strong, the issue price could be higher than the upper end of the price band.
Investors who are interested in participating in the Concord Biotech IPO should keep an eye on the GMP in the lead-up to the opening. If the GMP continues to fall, it could be a sign that the shares are less likely to list at a premium.
|Title||Concord Biotech IPO GMP Today: ₹240|
|Tags||#concordbiotech #ipo #gmp #stockmarket|
|Summary||The grey market premium (GMP) for Concord Biotech IPO today is ₹240. This means that investors are willing to pay ₹240 more for a share of Concord Biotech than the issue price of ₹705-741 per share.|
|Date||August 4, 2023|
The Concord Biotech IPO is a hotly anticipated IPO, and the GMP is a good indication of the strong demand for the shares. However, the GMP has been falling in recent days, so investors should keep an eye on it before making a decision to participate in the IPO.
- Gianluigi Buffon: Unveiling the Dimensions of a Football Icon – Net Worth, Height, Weight, Age, Birthday, Wikipedia, Who, Instagram
- Ahn Bo-hyun: Rising Star in South Korean Entertainment
- Kiersten Warren Net Worth 2023: Height, Weight, Age, Birthday, Wikipedia, Who, Instagram, Biography
- Sinead O’Connor: A Trailblazing Music Icon
- Amber Heard Net Worth 2023: Height, Weight, Age, Birthday, Wikipedia, Who, Instagram, Biography